Bullish & Foolish
Full VRCA fundamentals All 466 on the Survival Watch

VRCAVerrica Pharmaceuticals Inc.

Is Verrica Pharmaceuticals struggling financially?

Yes, by its own account. Verrica Pharmaceuticals told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Inventory

    The Company regularly reviews its inventory quantities and, when appropriate, records a provision for obsolete and excess inventory to derive the new cost basis, which takes into account the Company’s sales forecast and corresponding expiry dates.

    Form 10-Q, filed 12 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$82.8M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 6months

    If the burn speeds up

    Empty by Dec 2026

  • 9months

    If it eases off

    Empty by Mar 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$11.2M

÷

Cash burned over the last 12 months

$17.6M

What Verrica Pharmaceuticals told the SEC

…cash of $ 20.6 million as of March 31, 2026, combined with the uncertainty regarding the availability of additional funding, the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these financial statements are issued. The Company plans to address the conditions that raise substantial doubt regarding its ability to continue as a…

Verrica Pharmaceuticals Inc., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 124.6% share-count increase The company issued stock. Each share now owns 55.5% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 82% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt